Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. Get the full story on our sister site, Drug Delivery Business.
Nemaura Medical wins CE Mark for SugarBeat CGM
Nemaura Medical (NSDQ:NMRD) said yesterday that it won CE Mark approval for its SugarBEAT continuous glucose monitor. The SugarBEAT CGM is a flexible, disposable patch that’s connected to a rechargeable transmitter and Bluetooth-enabled smartphone app, designed to deliver glucose readings at five-minute intervals throughout the day. The company says the device allows users to spend more […]
Nemaura prices $2.5m offering to support launch of wearable glucose monitor
Nemaura Medical (NSDQ:NMRD) said this week that it priced a public offering of the company’s common stock and warrants, hoping to reel in $2.5 million in proceeds. The offering is slated to close today. Nemaura plans to use the offering’s proceeds to support the launch of its wearable glucose monitor in Europe, as well as the development of […]
Nemaura develops predictive algorithms for continuous glucose monitor
Nemaura Medical (NSDQ:NMRD) said today that it successfully developed predictive algorithms to support alarm functions in its sugarBeat continuous glucose monitoring system. The England-based company touted that its device’s alarm functionality can predict a user’s glucose level five minutes in advance with 98% accuracy, 10 minutes in advance with 95% accuracy and 15 minutes in advance with 90% accuracy. […]
Nemaura touts data from home-use study of wearable glucose monitor
Nemaura Medical (NSDQ:NMRD) said today that it launched a study of its wearable glucose monitor in the hopes of winning regulatory approval in the U.S. The England-based company touted positive interim data from the study, focusing on the at-home use of the sugarBeat device. Get the full story at our sister site, Drug Delivery Business News.
Nemaura Medical gears up to commercialize glucose monitor
Nemaura Medical (NSDQ:NMRD) said today that it placed an initial order to its UK-based contract manufacturer for 12,500 rechargeable transmitters, designed as part of the company’s sugarBeat glucose monitoring systems. Nemaura is readying for the commercial launch of its sugarBeat glucose monitor, pending CE Mark approval in the European Union. The device consists of a disposable, […]
Glooko names digital health veteran as CEO | Personnel Moves – April 17, 2018
Glooko named health tech veteran Russ Johannesson as its new chief executive this month, adding that the diabetes data management company’s former CEO, Rick Altinger, is slated to become EVP of corporate development. Johannesson previously served as the chief operating officer of Sharecare, a digital health and wellness platform. Before that he led sales, marketing and […]
Medtronic taps Harvard cardiologist Mauri for clinical research VP | Personnel Moves – April 10, 2018
Medtronic (NYSE:MDT) said last week it tapped Harvard Medical School professor and cardiologist Dr. Laura Mauri as its new vice president of global clinical research and analytics. In the new position, Dr. Mauri will direct dynamic global clinical research strategies as well as the development of novel analytical and data science solutions as the Fridley, Minn.-baesd […]
Preparing for commercial launch, Nemaura boosts manufacturing capabilities
Nemaura Medical (NSDQ:NMRD) plans to expand into new manufacturing facilities in preparation for the commercial launch of its non-invasive glucose monitoring system. The company expects to win CE Mark approval for its sugarBeat system in the coming months and also hopes to launch additional trials in the U.S. to support a regulatory bid with the FDA. […]
Nemaura Medical touts clinical trial data for non-invasive glucose monitor
Shares in Nemaura Medical (NSDQ:NMRD) jumped today after the company touted positive data from the European clinical trial program for its non-invasive sugarBeat glucose monitoring system. The summary results were taken from a 25-patient group in the three-stage trial, made up of 80% Type I diabetics and 20% Type II diabetics. Each patient continuously wore the sugarBeat […]
Nemaura uplists shares to NASDAQ exchange
Nemaura Medical (OTC:NMRD) said today that shares of its common stock were approved to list on the NASDAQ exchange. The medtech company’s shares are slated to start trading on Jan. 25 under its existing symbol. Get the full story at our sister site, Drug Delivery Business News.
MassDevice Network
@MassDevice
LinkedIn
YouTube